A Phase I/II Study of Immunotherapy With Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Adult Patients With Chronic Immune Thrombocytopenic Purpura
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Veltuzumab (Primary) ; Veltuzumab (Primary)
- Indications Thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences; Immunomedics
- 02 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 18 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.